WEBVTT
Kind: captions
Language: en

00:00:18.700 --> 00:00:22.210 

very<00:00:19.700> good<00:00:19.970> section<00:00:20.480> I<00:00:20.660> made<00:00:20.990> two<00:00:21.259> points<00:00:21.770> one

00:00:22.210 --> 00:00:22.220 
very good section I made two points one

00:00:22.220 --> 00:00:26.260 
very good section I made two points one
we<00:00:22.790> should<00:00:23.029> not<00:00:23.480> continue<00:00:24.230> with<00:00:25.270> double

00:00:26.260 --> 00:00:26.270 
we should not continue with double

00:00:26.270 --> 00:00:28.750 
we should not continue with double
antiplatelet<00:00:26.689> treatment<00:00:27.560> for<00:00:28.070> more<00:00:28.279> than<00:00:28.460> six

00:00:28.750 --> 00:00:28.760 
antiplatelet treatment for more than six

00:00:28.760 --> 00:00:32.679 
antiplatelet treatment for more than six
months<00:00:29.000> and<00:00:29.359> 2<00:00:30.109> we<00:00:30.740> should<00:00:30.910> really<00:00:31.910> use<00:00:32.449> the

00:00:32.679 --> 00:00:32.689 
months and 2 we should really use the

00:00:32.689 --> 00:00:34.780 
months and 2 we should really use the
new<00:00:32.870> generation<00:00:33.500> drug-eluting<00:00:33.980> stents<00:00:34.610> in

00:00:34.780 --> 00:00:34.790 
new generation drug-eluting stents in

00:00:34.790 --> 00:00:37.350 
new generation drug-eluting stents in
order<00:00:35.180> to<00:00:35.360> reduce<00:00:35.629> the<00:00:36.199> stent<00:00:36.500> thrombosis

00:00:37.350 --> 00:00:37.360 
order to reduce the stent thrombosis

00:00:37.360 --> 00:00:40.869 
order to reduce the stent thrombosis
during<00:00:38.360> this<00:00:38.629> third<00:00:39.080> hotline<00:00:39.650> session<00:00:40.129> Marco

00:00:40.869 --> 00:00:40.879 
during this third hotline session Marco

00:00:40.879 --> 00:00:42.940 
during this third hotline session Marco
Val<00:00:41.120> Jimmy<00:00:41.510> Lee<00:00:41.570> presented<00:00:42.230> the<00:00:42.320> prodigy

00:00:42.940 --> 00:00:42.950 
Val Jimmy Lee presented the prodigy

00:00:42.950 --> 00:00:45.280 
Val Jimmy Lee presented the prodigy
study<00:00:43.309> conducted<00:00:43.879> in<00:00:44.329> three<00:00:44.600> centers<00:00:45.050> in

00:00:45.280 --> 00:00:45.290 
study conducted in three centers in

00:00:45.290 --> 00:00:48.520 
study conducted in three centers in
which<00:00:45.980> more<00:00:46.250> than<00:00:46.329> 2,000<00:00:47.329> patients<00:00:47.629> scheduled

00:00:48.520 --> 00:00:48.530 
which more than 2,000 patients scheduled

00:00:48.530 --> 00:00:51.490 
which more than 2,000 patients scheduled
for<00:00:48.710> PCI<00:00:49.129> were<00:00:49.700> randomly<00:00:50.180> assigned<00:00:50.329> 30<00:00:51.200> days

00:00:51.490 --> 00:00:51.500 
for PCI were randomly assigned 30 days

00:00:51.500 --> 00:00:54.069 
for PCI were randomly assigned 30 days
after<00:00:51.890> stent<00:00:52.129> implantation<00:00:52.760> to<00:00:53.390> either<00:00:53.570> six

00:00:54.069 --> 00:00:54.079 
after stent implantation to either six

00:00:54.079 --> 00:00:56.560 
after stent implantation to either six
or<00:00:54.230> 24<00:00:55.129> months<00:00:55.160> of<00:00:55.579> dual<00:00:56.059> antiplatelet

00:00:56.560 --> 00:00:56.570 
or 24 months of dual antiplatelet

00:00:56.570 --> 00:00:59.799 
or 24 months of dual antiplatelet
therapy<00:00:57.670> the<00:00:58.670> primary<00:00:58.910> point<00:00:59.300> which<00:00:59.629> was

00:00:59.799 --> 00:00:59.809 
therapy the primary point which was

00:00:59.809 --> 00:01:02.200 
therapy the primary point which was
again<00:01:00.050> all<00:01:00.620> cause<00:01:00.829> death<00:01:01.010> and<00:01:01.190> I<00:01:01.250> NCBA<00:01:01.820> was

00:01:02.200 --> 00:01:02.210 
again all cause death and I NCBA was

00:01:02.210 --> 00:01:04.060 
again all cause death and I NCBA was
almost<00:01:02.660> identical<00:01:03.440> in<00:01:03.500> the<00:01:03.590> two<00:01:03.739> study<00:01:03.949> groups

00:01:04.060 --> 00:01:04.070 
almost identical in the two study groups

00:01:04.070 --> 00:01:06.850 
almost identical in the two study groups
ten<00:01:04.580> percent<00:01:05.000> in<00:01:05.119> one<00:01:05.270> group<00:01:05.590> 10.1<00:01:06.590> in<00:01:06.710> the

00:01:06.850 --> 00:01:06.860 
ten percent in one group 10.1 in the

00:01:06.860 --> 00:01:08.800 
ten percent in one group 10.1 in the
other<00:01:06.979> respect<00:01:07.580> to<00:01:07.640> the<00:01:07.759> bleeding<00:01:08.149> we<00:01:08.300> did<00:01:08.509> see

00:01:08.800 --> 00:01:08.810 
other respect to the bleeding we did see

00:01:08.810 --> 00:01:10.749 
other respect to the bleeding we did see
differences<00:01:09.410> because<00:01:10.130> the<00:01:10.340> key<00:01:10.520> safety

00:01:10.749 --> 00:01:10.759 
differences because the key safety

00:01:10.759 --> 00:01:14.560 
differences because the key safety
endpoint<00:01:11.360> which<00:01:11.660> was<00:01:11.899> again<00:01:12.170> bark<00:01:12.560> 5<00:01:13.369> 3<00:01:14.180> and<00:01:14.390> 2

00:01:14.560 --> 00:01:14.570 
endpoint which was again bark 5 3 and 2

00:01:14.570 --> 00:01:17.559 
endpoint which was again bark 5 3 and 2
was<00:01:15.170> more<00:01:15.800> than<00:01:15.979> two<00:01:16.160> times<00:01:16.190> higher<00:01:16.940> in<00:01:17.360> a

00:01:17.559 --> 00:01:17.569 
was more than two times higher in a

00:01:17.569 --> 00:01:20.169 
was more than two times higher in a
highly<00:01:18.020> significant<00:01:18.590> manner<00:01:18.770> a<00:01:19.039> patient<00:01:19.819> who

00:01:20.169 --> 00:01:20.179 
highly significant manner a patient who

00:01:20.179 --> 00:01:22.359 
highly significant manner a patient who
kept<00:01:20.450> on<00:01:20.660> repeating<00:01:21.080> before<00:01:21.440> 24<00:01:21.709> month<00:01:22.039> with

00:01:22.359 --> 00:01:22.369 
kept on repeating before 24 month with

00:01:22.369 --> 00:01:23.650 
kept on repeating before 24 month with
respect<00:01:22.580> to<00:01:22.819> the<00:01:22.940> short<00:01:23.179> duration<00:01:23.569> of

00:01:23.650 --> 00:01:23.660 
respect to the short duration of

00:01:23.660 --> 00:01:25.990 
respect to the short duration of
treatment<00:01:23.810> our<00:01:24.380> study<00:01:24.770> can<00:01:25.160> lead<00:01:25.520> us<00:01:25.550> to<00:01:25.970> a

00:01:25.990 --> 00:01:26.000 
treatment our study can lead us to a

00:01:26.000 --> 00:01:27.490 
treatment our study can lead us to a
very<00:01:26.209> simple<00:01:26.539> conclusion<00:01:26.720> that<00:01:27.229> this

00:01:27.490 --> 00:01:27.500 
very simple conclusion that this

00:01:27.500 --> 00:01:29.469 
very simple conclusion that this
continuation<00:01:28.039> of<00:01:28.310> Torpedo<00:01:28.670> after<00:01:28.940> 6<00:01:29.149> month<00:01:29.330> is

00:01:29.469 --> 00:01:29.479 
continuation of Torpedo after 6 month is

00:01:29.479 --> 00:01:31.900 
continuation of Torpedo after 6 month is
safe<00:01:29.720> in<00:01:29.929> patient<00:01:30.289> probably<00:01:30.530> even<00:01:30.679> safer<00:01:31.610> than

00:01:31.900 --> 00:01:31.910 
safe in patient probably even safer than

00:01:31.910 --> 00:01:33.639 
safe in patient probably even safer than
prolonging<00:01:32.209> crop<00:01:32.690> eager<00:01:32.929> for<00:01:33.140> more<00:01:33.259> than<00:01:33.440> six

00:01:33.639 --> 00:01:33.649 
prolonging crop eager for more than six

00:01:33.649 --> 00:01:39.160 
prolonging crop eager for more than six
months<00:01:34.630> at<00:01:35.630> this<00:01:36.110> third<00:01:36.590> ASC<00:01:37.660> 2011<00:01:38.660> hotline

00:01:39.160 --> 00:01:39.170 
months at this third ASC 2011 hotline

00:01:39.170 --> 00:01:41.710 
months at this third ASC 2011 hotline
lorenz<00:01:39.890> Raber<00:01:40.280> presented<00:01:41.149> the<00:01:41.239> results<00:01:41.270> of

00:01:41.710 --> 00:01:41.720 
lorenz Raber presented the results of

00:01:41.720 --> 00:01:44.050 
lorenz Raber presented the results of
the<00:01:41.810> van<00:01:42.080> rotterdam<00:01:42.860> cohort<00:01:43.429> a<00:01:43.640> study<00:01:43.970> that's

00:01:44.050 --> 00:01:44.060 
the van rotterdam cohort a study that's

00:01:44.060 --> 00:01:46.600 
the van rotterdam cohort a study that's
compared<00:01:44.690> the<00:01:44.899> safety<00:01:45.349> and<00:01:45.530> rate<00:01:46.130> of<00:01:46.160> late

00:01:46.600 --> 00:01:46.610 
compared the safety and rate of late

00:01:46.610 --> 00:01:48.999 
compared the safety and rate of late
stent<00:01:47.000> thrombosis<00:01:47.119> of<00:01:47.869> the<00:01:48.170> unrestricted<00:01:48.770> use

00:01:48.999 --> 00:01:49.009 
stent thrombosis of the unrestricted use

00:01:49.009 --> 00:01:51.910 
stent thrombosis of the unrestricted use
of<00:01:49.369> the<00:01:49.670> everolimus<00:01:50.209> eluting<00:01:50.869> stent<00:01:51.170> compared

00:01:51.910 --> 00:01:51.920 
of the everolimus eluting stent compared

00:01:51.920 --> 00:01:54.279 
of the everolimus eluting stent compared
with<00:01:52.009> earlier<00:01:52.550> generation<00:01:53.179> sirolimus<00:01:53.780> and

00:01:54.279 --> 00:01:54.289 
with earlier generation sirolimus and

00:01:54.289 --> 00:01:56.260 
with earlier generation sirolimus and
paclitaxel<00:01:54.530> eluting<00:01:55.520> stents<00:01:55.849> in<00:01:56.000> a

00:01:56.260 --> 00:01:56.270 
paclitaxel eluting stents in a

00:01:56.270 --> 00:02:00.130 
paclitaxel eluting stents in a
population<00:01:56.869> of<00:01:57.069> 12,000<00:01:58.069> 339<00:01:59.140> consecutively

00:02:00.130 --> 00:02:00.140 
population of 12,000 339 consecutively

00:02:00.140 --> 00:02:03.070 
population of 12,000 339 consecutively
enrolled<00:02:00.649> patients<00:02:01.000> stay<00:02:02.000> benefit<00:02:02.660> in<00:02:02.929> terms

00:02:03.070 --> 00:02:03.080 
enrolled patients stay benefit in terms

00:02:03.080 --> 00:02:06.400 
enrolled patients stay benefit in terms
of<00:02:03.560> everolimus<00:02:04.340> eluting<00:02:05.060> extent<00:02:05.509> was<00:02:05.840> mainly

00:02:06.400 --> 00:02:06.410 
of everolimus eluting extent was mainly

00:02:06.410 --> 00:02:10.270 
of everolimus eluting extent was mainly
pronounced<00:02:07.340> during<00:02:07.819> the<00:02:08.270> late<00:02:09.170> time<00:02:09.590> period

00:02:10.270 --> 00:02:10.280 
pronounced during the late time period

00:02:10.280 --> 00:02:13.449 
pronounced during the late time period
studies<00:02:10.759> beyond<00:02:11.690> one<00:02:12.470> year<00:02:12.500> with<00:02:13.160> a

00:02:13.449 --> 00:02:13.459 
studies beyond one year with a

00:02:13.459 --> 00:02:17.220 
studies beyond one year with a
significant<00:02:14.270> relative<00:02:15.170> risk<00:02:15.530> reduction<00:02:15.800> of

00:02:17.220 --> 00:02:17.230 
significant relative risk reduction of

00:02:17.230 --> 00:02:19.630 
significant relative risk reduction of
sixty-seven<00:02:18.230> percent<00:02:18.260> in<00:02:19.070> favor<00:02:19.130> of

00:02:19.630 --> 00:02:19.640 
sixty-seven percent in favor of

00:02:19.640 --> 00:02:22.270 
sixty-seven percent in favor of
everolimus<00:02:20.450> eluting<00:02:21.230> stent<00:02:21.530> as<00:02:21.710> compared<00:02:22.220> to

00:02:22.270 --> 00:02:22.280 
everolimus eluting stent as compared to

00:02:22.280 --> 00:02:24.340 
everolimus eluting stent as compared to
sirolimus-eluting<00:02:23.090> stand

00:02:24.340 --> 00:02:24.350 
sirolimus-eluting stand

00:02:24.350 --> 00:02:26.740 
sirolimus-eluting stand
and<00:02:24.470> resulting<00:02:25.250> in<00:02:25.490> a<00:02:25.700> significant<00:02:26.600> risk

00:02:26.740 --> 00:02:26.750 
and resulting in a significant risk

00:02:26.750 --> 00:02:31.030 
and resulting in a significant risk
reduction<00:02:27.470> of<00:02:28.600> seventy-six<00:02:29.600> percent<00:02:30.040> in

00:02:31.030 --> 00:02:31.040 
reduction of seventy-six percent in

00:02:31.040 --> 00:02:33.670 
reduction of seventy-six percent in
favor<00:02:31.100> of<00:02:31.610> the<00:02:32.000> avaril<00:02:32.450> moose<00:02:32.780> as<00:02:32.990> compared<00:02:33.620> to

00:02:33.670 --> 00:02:33.680 
favor of the avaril moose as compared to

00:02:33.680 --> 00:02:37.270 
favor of the avaril moose as compared to
the<00:02:33.800> parklet<00:02:34.370> axel<00:02:35.260> eluting<00:02:36.260> stent<00:02:36.890> the

00:02:37.270 --> 00:02:37.280 
the parklet axel eluting stent the

00:02:37.280 --> 00:02:39.790 
the parklet axel eluting stent the
results<00:02:37.820> was<00:02:38.060> the<00:02:38.390> newer<00:02:38.720> stent<00:02:39.200> newer

00:02:39.790 --> 00:02:39.800 
results was the newer stent newer

00:02:39.800 --> 00:02:41.530 
results was the newer stent newer
generation<00:02:40.370> stands<00:02:40.670> appear<00:02:40.940> to<00:02:41.030> be<00:02:41.150> excellent

00:02:41.530 --> 00:02:41.540 
generation stands appear to be excellent

00:02:41.540 --> 00:02:44.320 
generation stands appear to be excellent
both<00:02:42.350> in<00:02:42.500> terms<00:02:42.650> of<00:02:42.830> efficacy<00:02:43.130> and<00:02:43.550> safety<00:02:43.670> and

00:02:44.320 --> 00:02:44.330 
both in terms of efficacy and safety and

00:02:44.330 --> 00:02:46.390 
both in terms of efficacy and safety and
they<00:02:44.840> translate<00:02:45.350> into<00:02:45.530> clinical<00:02:45.980> outcome

00:02:46.390 --> 00:02:46.400 
they translate into clinical outcome

00:02:46.400 --> 00:02:49.060 
they translate into clinical outcome
into<00:02:47.120> superior<00:02:47.510> clinical<00:02:47.900> outcomes<00:02:48.260> and<00:02:48.500> I

00:02:49.060 --> 00:02:49.070 
into superior clinical outcomes and I

00:02:49.070 --> 00:02:51.040 
into superior clinical outcomes and I
think<00:02:49.280> that<00:02:49.430> is<00:02:49.580> a<00:02:49.790> stark<00:02:50.240> contrast<00:02:50.330> with<00:02:51.020> what

00:02:51.040 --> 00:02:51.050 
think that is a stark contrast with what

00:02:51.050 --> 00:02:54.010 
think that is a stark contrast with what
was<00:02:51.380> seen<00:02:51.560> a<00:02:51.590> few<00:02:51.800> years<00:02:52.010> ago<00:02:52.250> at<00:02:52.610> the<00:02:53.000> ESC<00:02:53.330> 2006

00:02:54.010 --> 00:02:54.020 
was seen a few years ago at the ESC 2006

00:02:54.020 --> 00:02:55.270 
was seen a few years ago at the ESC 2006
where<00:02:54.230> there<00:02:54.350> were<00:02:54.410> a<00:02:54.440> lot<00:02:54.620> of<00:02:54.650> concerns<00:02:55.070> with

00:02:55.270 --> 00:02:55.280 
where there were a lot of concerns with

00:02:55.280 --> 00:03:50.130 
where there were a lot of concerns with
the<00:02:55.400> first<00:02:55.730> generation<00:02:56.270> drug-eluting<00:02:56.600> stents

00:03:50.130 --> 00:03:50.140 

00:03:50.140 --> 00:03:52.660 

at<00:03:51.140> one<00:03:51.409> of<00:03:51.530> the<00:03:51.590> two<00:03:51.739> clinical<00:03:52.219> trial<00:03:52.519> update

00:03:52.660 --> 00:03:52.670 
at one of the two clinical trial update

00:03:52.670 --> 00:03:55.209 
at one of the two clinical trial update
sessions<00:03:53.390> jean-claude<00:03:53.870> tardif<00:03:54.500> presented

00:03:55.209 --> 00:03:55.219 
sessions jean-claude tardif presented

00:03:55.219 --> 00:03:57.399 
sessions jean-claude tardif presented
the<00:03:55.340> echocardiography<00:03:56.090> analysis<00:03:56.959> conducted

00:03:57.399 --> 00:03:57.409 
the echocardiography analysis conducted

00:03:57.409 --> 00:04:01.179 
the echocardiography analysis conducted
on<00:03:57.889> 611<00:03:58.819> patients<00:03:59.420> in<00:03:59.540> the<00:03:59.659> shift<00:03:59.959> study<00:04:00.439> shift

00:04:01.179 --> 00:04:01.189 
on 611 patients in the shift study shift

00:04:01.189 --> 00:04:04.240 
on 611 patients in the shift study shift
was<00:04:01.370> reported<00:04:02.000> as<00:04:02.269> an<00:04:02.420> esc<00:04:02.840> 2010<00:04:03.769> hotline

00:04:04.240 --> 00:04:04.250 
was reported as an esc 2010 hotline

00:04:04.250 --> 00:04:06.849 
was reported as an esc 2010 hotline
session<00:04:04.700> by<00:04:05.060> michele<00:04:05.450> commercia<00:04:05.870> study

00:04:06.849 --> 00:04:06.859 
session by michele commercia study

00:04:06.859 --> 00:04:10.030 
session by michele commercia study
included<00:04:07.689> 6500<00:04:08.689> patients<00:04:09.079> with<00:04:09.200> moderate<00:04:09.650> to

00:04:10.030 --> 00:04:10.040 
included 6500 patients with moderate to

00:04:10.040 --> 00:04:12.129 
included 6500 patients with moderate to
severe<00:04:10.400> heart<00:04:10.700> failure<00:04:10.790> with<00:04:11.510> heart<00:04:11.750> rates<00:04:11.959> of

00:04:12.129 --> 00:04:12.139 
severe heart failure with heart rates of

00:04:12.139 --> 00:04:14.349 
severe heart failure with heart rates of
70<00:04:12.470> beats<00:04:12.620> per<00:04:12.769> minute<00:04:13.099> or<00:04:13.250> more<00:04:13.280> and<00:04:13.790> already

00:04:14.349 --> 00:04:14.359 
70 beats per minute or more and already

00:04:14.359 --> 00:04:16.180 
70 beats per minute or more and already
receiving<00:04:14.810> optimal<00:04:15.470> recommended<00:04:16.039> therapy

00:04:16.180 --> 00:04:16.190 
receiving optimal recommended therapy

00:04:16.190 --> 00:04:18.640 
receiving optimal recommended therapy
they<00:04:17.000> received<00:04:17.359> either<00:04:17.599> evaporating<00:04:18.470> or

00:04:18.640 --> 00:04:18.650 
they received either evaporating or

00:04:18.650 --> 00:04:20.379 
they received either evaporating or
placebo<00:04:18.829> and<00:04:19.549> the<00:04:19.910> study<00:04:20.180> has<00:04:20.359> demonstrated

00:04:20.379 --> 00:04:20.389 
placebo and the study has demonstrated

00:04:20.389 --> 00:04:22.839 
placebo and the study has demonstrated
that<00:04:21.229> adding<00:04:21.650> Eve<00:04:21.769> Aberdeen<00:04:22.220> led<00:04:22.669> to<00:04:22.820> a

00:04:22.839 --> 00:04:22.849 
that adding Eve Aberdeen led to a

00:04:22.849 --> 00:04:24.310 
that adding Eve Aberdeen led to a
significant<00:04:23.509> eighteen<00:04:23.870> percent<00:04:24.020> reduction

00:04:24.310 --> 00:04:24.320 
significant eighteen percent reduction

00:04:24.320 --> 00:04:26.610 
significant eighteen percent reduction
in<00:04:24.830> cardiovascular<00:04:25.550> death<00:04:26.210> and

00:04:26.610 --> 00:04:26.620 
in cardiovascular death and

00:04:26.620 --> 00:04:30.070 
in cardiovascular death and
hospitalization<00:04:27.620> for<00:04:27.770> heart<00:04:27.979> failure<00:04:29.080> the

00:04:30.070 --> 00:04:30.080 
hospitalization for heart failure the

00:04:30.080 --> 00:04:32.290 
hospitalization for heart failure the
results<00:04:30.410> I<00:04:30.470> think<00:04:30.710> are<00:04:30.830> really<00:04:31.460> pretty

00:04:32.290 --> 00:04:32.300 
results I think are really pretty

00:04:32.300 --> 00:04:34.689 
results I think are really pretty
spectacular<00:04:32.800> there<00:04:33.800> were<00:04:33.860> significant

00:04:34.689 --> 00:04:34.699 
spectacular there were significant

00:04:34.699 --> 00:04:36.870 
spectacular there were significant
reductions<00:04:35.240> in<00:04:35.330> ventricular<00:04:35.830> volumes

00:04:36.870 --> 00:04:36.880 
reductions in ventricular volumes

00:04:36.880 --> 00:04:39.550 
reductions in ventricular volumes
improvement<00:04:37.880> in<00:04:38.120> ejection<00:04:38.750> fraction<00:04:39.320> and

00:04:39.550 --> 00:04:39.560 
improvement in ejection fraction and

00:04:39.560 --> 00:04:42.370 
improvement in ejection fraction and
this<00:04:40.250> was<00:04:40.460> over<00:04:41.060> and<00:04:41.180> above<00:04:41.270> what<00:04:41.780> you<00:04:42.199> get<00:04:42.349> a

00:04:42.370 --> 00:04:42.380 
this was over and above what you get a

00:04:42.380 --> 00:04:44.230 
this was over and above what you get a
bit<00:04:42.620> with<00:04:42.740> a<00:04:42.770> beta<00:04:43.010> blocker<00:04:43.130> and<00:04:43.729> a<00:04:44.060> rat

00:04:44.230 --> 00:04:44.240 
bit with a beta blocker and a rat

00:04:44.240 --> 00:04:45.909 
bit with a beta blocker and a rat
inhibitor<00:04:44.750> that<00:04:44.930> we<00:04:45.080> were<00:04:45.199> actually<00:04:45.349> able<00:04:45.710> to

00:04:45.909 --> 00:04:45.919 
inhibitor that we were actually able to

00:04:45.919 --> 00:04:50.260 
inhibitor that we were actually able to
link<00:04:46.400> the<00:04:47.680> magnitude<00:04:48.680> of<00:04:48.919> lv<00:04:49.370> dysfunction<00:04:49.550> as

00:04:50.260 --> 00:04:50.270 
link the magnitude of lv dysfunction as

00:04:50.270 --> 00:04:52.870 
link the magnitude of lv dysfunction as
defined<00:04:50.930> by<00:04:51.169> echocardiography<00:04:51.710> with<00:04:52.520> future

00:04:52.870 --> 00:04:52.880 
defined by echocardiography with future

00:04:52.880 --> 00:04:54.760 
defined by echocardiography with future
outcomes<00:04:53.300> so<00:04:53.510> they're<00:04:53.870> very<00:04:53.900> there's<00:04:54.409> a<00:04:54.470> nice

00:04:54.760 --> 00:04:54.770 
outcomes so they're very there's a nice

00:04:54.770 --> 00:04:57.790 
outcomes so they're very there's a nice
story<00:04:55.159> between<00:04:55.880> the<00:04:56.810> magnitude<00:04:57.440> of<00:04:57.530> lv

00:04:57.790 --> 00:04:57.800 
story between the magnitude of lv

00:04:57.800 --> 00:05:00.100 
story between the magnitude of lv
dysfunction<00:04:58.270> clinical<00:04:59.270> outcomes<00:04:59.690> and<00:04:59.900> then

00:05:00.100 --> 00:05:00.110 
dysfunction clinical outcomes and then

00:05:00.110 --> 00:05:03.399 
dysfunction clinical outcomes and then
the<00:05:00.650> improvement<00:05:01.430> of<00:05:01.639> lv<00:05:02.599> function<00:05:02.810> and

00:05:03.399 --> 00:05:03.409 
the improvement of lv function and

00:05:03.409 --> 00:05:05.320 
the improvement of lv function and
volumes<00:05:03.919> and<00:05:04.130> improvement<00:05:04.909> in<00:05:05.000> clinical

00:05:05.320 --> 00:05:05.330 
volumes and improvement in clinical

00:05:05.330 --> 00:05:12.339 
volumes and improvement in clinical
outcomes<00:05:09.820> for<00:05:10.820> the<00:05:10.940> first<00:05:11.150> time<00:05:11.330> the<00:05:11.720> esc<00:05:12.199> has

00:05:12.339 --> 00:05:12.349 
outcomes for the first time the esc has

00:05:12.349 --> 00:05:13.930 
outcomes for the first time the esc has
developed<00:05:12.740> specific<00:05:13.250> guidelines<00:05:13.669> on

00:05:13.930 --> 00:05:13.940 
developed specific guidelines on

00:05:13.940 --> 00:05:16.659 
developed specific guidelines on
dyslipidemia<00:05:14.810> jointly<00:05:15.560> with<00:05:15.740> the<00:05:16.009> european

00:05:16.659 --> 00:05:16.669 
dyslipidemia jointly with the european

00:05:16.669 --> 00:05:19.510 
dyslipidemia jointly with the european
atherosclerosis<00:05:17.259> society<00:05:18.259> zeljko<00:05:19.190> Reiner

00:05:19.510 --> 00:05:19.520 
atherosclerosis society zeljko Reiner

00:05:19.520 --> 00:05:21.550 
atherosclerosis society zeljko Reiner
who<00:05:19.880> chaired<00:05:20.210> this<00:05:20.419> new<00:05:20.659> document<00:05:21.139> shared

00:05:21.550 --> 00:05:21.560 
who chaired this new document shared

00:05:21.560 --> 00:05:23.560 
who chaired this new document shared
some<00:05:21.919> of<00:05:22.009> their<00:05:22.159> key<00:05:22.340> messages<00:05:22.880> the<00:05:23.180> clinical

00:05:23.560 --> 00:05:23.570 
some of their key messages the clinical

00:05:23.570 --> 00:05:27.279 
some of their key messages the clinical
practice<00:05:23.960> with<00:05:24.259> us<00:05:24.289> I<00:05:24.590> would<00:05:25.550> say<00:05:25.759> first<00:05:26.539> LDL

00:05:27.279 --> 00:05:27.289 
practice with us I would say first LDL

00:05:27.289 --> 00:05:29.649 
practice with us I would say first LDL
cholesterol<00:05:27.530> is<00:05:28.190> the<00:05:28.340> main<00:05:28.520> target<00:05:29.090> and<00:05:29.360> has

00:05:29.649 --> 00:05:29.659 
cholesterol is the main target and has

00:05:29.659 --> 00:05:33.430 
cholesterol is the main target and has
to<00:05:29.840> be<00:05:30.159> treated<00:05:31.159> properly<00:05:31.639> what<00:05:32.300> is<00:05:32.479> new<00:05:32.780> we

00:05:33.430 --> 00:05:33.440 
to be treated properly what is new we

00:05:33.440 --> 00:05:37.240 
to be treated properly what is new we
have<00:05:33.590> introduced<00:05:34.190> score<00:05:34.970> tables<00:05:36.220> which<00:05:37.220> are

00:05:37.240 --> 00:05:37.250 
have introduced score tables which are

00:05:37.250 --> 00:05:39.820 
have introduced score tables which are
taken<00:05:37.909> into<00:05:38.120> consideration<00:05:38.650> HDL<00:05:39.650> cholesterol

00:05:39.820 --> 00:05:39.830 
taken into consideration HDL cholesterol

00:05:39.830 --> 00:05:45.010 
taken into consideration HDL cholesterol
we<00:05:40.789> introduce<00:05:42.340> four<00:05:43.340> steps<00:05:43.880> of<00:05:44.210> risk<00:05:44.659> I<00:05:44.960> would

00:05:45.010 --> 00:05:45.020 
we introduce four steps of risk I would

00:05:45.020 --> 00:05:47.700 
we introduce four steps of risk I would
say<00:05:45.380> and<00:05:45.590> another<00:05:46.220> important<00:05:46.909> issue<00:05:47.120> in<00:05:47.419> this

00:05:47.700 --> 00:05:47.710 
say and another important issue in this

00:05:47.710 --> 00:05:53.500 
say and another important issue in this
guidelines<00:05:48.710> is<00:05:48.950> combined<00:05:49.430> therapy

00:05:53.500 --> 00:05:53.510 

00:05:53.510 --> 00:05:58.460 

Paris<00:05:54.510> 2011<00:05:55.290> has<00:05:55.830> been<00:05:56.130> a<00:05:56.370> great<00:05:56.970> success<00:05:57.470> both

00:05:58.460 --> 00:05:58.470 
Paris 2011 has been a great success both

00:05:58.470 --> 00:06:01.880 
Paris 2011 has been a great success both
in<00:05:58.740> terms<00:05:58.980> of<00:05:59.690> number<00:06:00.690> of<00:06:00.840> Delegates<00:06:01.380> because

00:06:01.880 --> 00:06:01.890 
in terms of number of Delegates because

00:06:01.890 --> 00:06:05.030 
in terms of number of Delegates because
we<00:06:02.190> have<00:06:02.340> broken<00:06:02.850> as<00:06:03.270> expected<00:06:04.140> the<00:06:04.380> records

00:06:05.030 --> 00:06:05.040 
we have broken as expected the records

00:06:05.040 --> 00:06:08.030 
we have broken as expected the records
for<00:06:05.550> the<00:06:05.610> ESC<00:06:06.300> with<00:06:06.540> more<00:06:06.810> than<00:06:07.040> 33,000

00:06:08.030 --> 00:06:08.040 
for the ESC with more than 33,000

00:06:08.040 --> 00:06:11.780 
for the ESC with more than 33,000
delegates<00:06:08.570> coming<00:06:09.570> from<00:06:09.860> 150<00:06:10.860> countries<00:06:11.070> with

00:06:11.780 --> 00:06:11.790 
delegates coming from 150 countries with

00:06:11.790 --> 00:06:13.640 
delegates coming from 150 countries with
really<00:06:12.270> a<00:06:12.420> global<00:06:13.080> meeting<00:06:13.290> on

00:06:13.640 --> 00:06:13.650 
really a global meeting on

00:06:13.650 --> 00:06:15.860 
really a global meeting on
cardiovascular<00:06:14.010> diseases<00:06:15.000> and<00:06:15.300> at<00:06:15.720> the

00:06:15.860 --> 00:06:15.870 
cardiovascular diseases and at the

00:06:15.870 --> 00:06:18.440 
cardiovascular diseases and at the
moment<00:06:16.050> it<00:06:16.680> is<00:06:16.740> the<00:06:17.010> largest<00:06:17.190> meeting<00:06:18.060> in<00:06:18.300> the

00:06:18.440 --> 00:06:18.450 
moment it is the largest meeting in the

00:06:18.450 --> 00:06:21.410 
moment it is the largest meeting in the
world<00:06:18.690> but<00:06:19.620> it<00:06:19.740> was<00:06:19.920> also<00:06:20.190> a<00:06:20.430> success<00:06:20.940> in<00:06:21.150> terms

00:06:21.410 --> 00:06:21.420 
world but it was also a success in terms

00:06:21.420 --> 00:06:25.670 
world but it was also a success in terms
of<00:06:21.830> quality<00:06:22.830> and<00:06:23.160> we<00:06:23.970> heard<00:06:24.150> exciting<00:06:25.140> results

00:06:25.670 --> 00:06:25.680 
of quality and we heard exciting results

00:06:25.680 --> 00:06:28.490 
of quality and we heard exciting results
about<00:06:25.980> major<00:06:26.640> registries<00:06:27.450> whether<00:06:27.960> in<00:06:28.140> Europe

00:06:28.490 --> 00:06:28.500 
about major registries whether in Europe

00:06:28.500 --> 00:06:31.490 
about major registries whether in Europe
or<00:06:28.740> global<00:06:29.280> and<00:06:29.520> also<00:06:30.510> very<00:06:30.840> interesting

00:06:31.490 --> 00:06:31.500 
or global and also very interesting

00:06:31.500 --> 00:06:34.400 
or global and also very interesting
hotlines<00:06:32.040> with<00:06:32.370> new<00:06:32.700> clinical<00:06:33.180> trials<00:06:33.720> so<00:06:34.260> it

00:06:34.400 --> 00:06:34.410 
hotlines with new clinical trials so it

00:06:34.410 --> 00:06:36.740 
hotlines with new clinical trials so it
was<00:06:34.620> an<00:06:34.800> outstanding<00:06:35.100> meeting<00:06:35.970> but<00:06:36.450> we<00:06:36.630> have

00:06:36.740 --> 00:06:36.750 
was an outstanding meeting but we have

00:06:36.750 --> 00:06:39.050 
was an outstanding meeting but we have
to<00:06:36.930> look<00:06:37.140> towards<00:06:37.560> the<00:06:37.650> future<00:06:37.740> and<00:06:38.430> the

00:06:39.050 --> 00:06:39.060 
to look towards the future and the

00:06:39.060 --> 00:06:42.250 
to look towards the future and the
future<00:06:39.090> the<00:06:39.810> annual<00:06:40.080> meeting<00:06:40.110> of<00:06:40.680> the<00:06:40.770> esc<00:06:41.670> in

00:06:42.250 --> 00:06:42.260 
future the annual meeting of the esc in

00:06:42.260 --> 00:06:45.980 
future the annual meeting of the esc in
2012<00:06:43.260> and<00:06:43.590> as<00:06:44.220> you<00:06:44.640> may<00:06:44.790> know<00:06:45.030> we<00:06:45.600> will<00:06:45.780> welcome

00:06:45.980 --> 00:06:45.990 
2012 and as you may know we will welcome

00:06:45.990 --> 00:06:48.800 
2012 and as you may know we will welcome
you<00:06:46.440> in<00:06:46.650> the<00:06:46.950> city<00:06:47.340> of<00:06:47.370> Munich<00:06:47.880> in<00:06:48.060> Germany<00:06:48.090> and

00:06:48.800 --> 00:06:48.810 
you in the city of Munich in Germany and

00:06:48.810 --> 00:06:53.690 
you in the city of Munich in Germany and
the<00:06:49.520> spotlight<00:06:50.520> of<00:06:51.080> 2012<00:06:52.080> is<00:06:52.710> from<00:06:53.280> bench<00:06:53.550> to

00:06:53.690 --> 00:06:53.700 
the spotlight of 2012 is from bench to

00:06:53.700 --> 00:06:56.300 
the spotlight of 2012 is from bench to
bedside<00:06:53.900> so<00:06:54.900> I<00:06:54.930> look<00:06:55.260> forward<00:06:55.470> to<00:06:55.620> welcoming

00:06:56.300 --> 00:06:56.310 
bedside so I look forward to welcoming

00:06:56.310 --> 00:06:59.780 
bedside so I look forward to welcoming
all<00:06:56.550> of<00:06:56.610> you<00:06:57.060> in<00:06:57.270> unique

